Back to search results

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Non-Muscle Invasive Bladder Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Michael G Oefelein Clinical Trials ( Site 0053), Bakersfield, California, United States

    Study coordinator · 661-310-1063

  • Moffitt Cancer Center ( Site 0057), Tampa, Florida, United States

    Study coordinator · 888-663-4488

  • Northwestern University ( Site 0051), Chicago, Illinois, United States

    Study coordinator · 312-695-1102

  • Johns Hopkins University ( Site 0055), Baltimore, Maryland, United States

    Study coordinator · 410-614-0009

  • Princess Margaret Cancer Centre ( Site 0003), Toronto, Ontario, Canada

    Study coordinator · 4169462246

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002), Sherbrooke, Quebec, Canada

    Study coordinator · 8193461110 x13446

  • Hôpital Claude Huriez ( Site 0012), Lille, Nord, France

  • HENRI MONDOR HOSPITAL ( Site 0011), Créteil, Val-de-Marne, France

  • Gustave Roussy ( Site 0013), Villejuif, Val-de-Marne, France

  • Erasmus Medisch Centrum ( Site 0032), Rotterdam, South Holland, Netherlands

    Study coordinator · +31107041566

  • Hospital Universitario Virgen de la Victoria ( Site 0043), Málaga, Andalusia, Spain

    Study coordinator · +34951032095

  • Hospital Universitario 12 de Octubre ( Site 0042), Madrid, Spain

    Study coordinator · +34913908121

  • St Bartholomew s Hospital ( Site 0061), London, London, City of, United Kingdom

    Study coordinator · +4407535510363
Study leads

  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

View source on ClinicalTrials.gov(opens in a new tab)